biostudies-literatureUnknownAlolayan S<b>Introduction:</b> Based on previously published US Diabetes Prevention Program (DPP) cost-effectiveness analyses (CEAs), metformin continues to be promoted as "cost-effective." We reviewed a 10-year CEA to assess this. Treatment alternatives included placebo, branded metformin and individual lifestyle modification. Following the original CEA, we added group lifestyle as a modeled alternative. <b>Methods:</b> Original published data were taken as given and re-analyzed according to accepted principles for calculating incremental cost-effectiveness ratios (ICERs). With more than 2 treatments, these require attention to the rankings of interventions according to cost or effect prior to stipulating appropriate ICERs to calculate. <b>Results:</b> With appropriate ICER calculations, metformin American journal of lifestyle medicine15598276251315415https://www.ebi.ac.uk/biostudies/studies/S-EPMC11752154biostudies-literatureIncremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study.PMC11752154Doucette JRittenhouse BESegal ARAlolayan SEguale TfalseIncremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study.<b>Introduction:</b> Based on previously published US Diabetes Prevention Program (DPP) cost-effectiveness analyses (CEAs), metformin continues to be promoted as "cost-effective." We reviewed a 10-year CEA to assess this. Treatment alternatives included placebo, branded metformin and individual lifestyle modification. Following the original CEA, we added group lifestyle as a modeled alternative. <b>Methods:</b> Original published data were taken as given and re-analyzed according to accepted principles for calculating incremental cost-effectiveness ratios (ICERs). With more than 2 treatments, these require attention to the rankings of interventions according to cost or effect prior to stipulating appropriate ICERs to calculate. <b>Results:</b> With appropriate ICER calculations, metformin 2025-01-01T00:00:00Z2025 Jan2025-04-05T00:25:30.823Z2025-04-05T00:25:30.823ZS-EPMC117521543985032210.1177/15598276251315415